Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Genmab A/S - American Depositary Shares (NQ:GMAB)

35.49 +0.13 (+0.38%)
Streaming Delayed Price Updated: 3:29 PM EDT, Sep 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
For those who appreciate value investing, GENMAB A/S -SP ADR (NASDAQ:GMAB) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout. 
Via Chartmill
News headline image
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable. ↗
NASDAQ:GMAB is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
NASDAQ:GMAB appears to be flying under the radar despite its strong fundamentals. ↗
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
Via Chartmill
News headline image
Looking for growth without the hefty price tag? Consider NASDAQ:GMAB. ↗
While growth is established for GENMAB A/S -SP ADR (NASDAQ:GMAB), the stock's valuation remains reasonable. 
Via Chartmill
News headline image
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
From Genmab A/S
Via Business Wire
News headline image
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank. ↗
NASDAQ:GMAB, a growth stock which is not overvalued. 
Via Chartmill
News headline image
A Closer Look at 10 Analyst Recommendations For Genmab ↗
 
Via Benzinga
News headline image
Preview: Genmab's Earnings ↗
 
Via Benzinga
News headline image
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
News headline image
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
News headline image
Why NASDAQ:GMAB Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Why GENMAB A/S -SP ADR (NASDAQ:GMAB) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
12 Analysts Have This To Say About Genmab ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB qualifies as a high growth stock and is consolidating. ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
For those who appreciate value investing, NASDAQ:GMAB is a compelling option with its solid fundamentals. ↗
Despite its impressive fundamentals, GENMAB A/S -SP ADR (NASDAQ:GMAB) remains undervalued. 
Via Chartmill
News headline image
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
News headline image
When you look at NASDAQ:GMAB, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
News headline image
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced. ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
NASDAQ:GMAB is an undervalued gem with solid fundamentals. ↗
Don't overlook GENMAB A/S -SP ADR (NASDAQ:GMAB)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
News headline image
NASDAQ:GMAB, a growth stock which is not overvalued. ↗
NASDAQ:GMAB is showing good growth, while it is not too expensive. 
Via Chartmill
News headline image
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying. ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Expert Ratings For Genmab ↗
 
Via Benzinga
News headline image
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?. ↗
Is GENMAB A/S -SP ADR (NASDAQ:GMAB) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
News headline image
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. ↗
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
News headline image
NASDAQ:GMAB is showing good growth, while it is not too expensive. ↗
GENMAB A/S -SP ADR (NASDAQ:GMAB) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Decoding 10 Analyst Evaluations For Genmab ↗
 
Via Benzinga
News headline image
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.